Comparison of properties of tumor necrosis factor-α converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domains

Abstract

The crystal structural data of TACE, MMP-1, MMP-2, MMP-3 and MMP-9 were obtained from PDB database, and then their catalytic domains’ properties including conformation, molecular surface hydrophobicity and electrostatic potential were analyzed and compared by using Insight II molecular modeling software. It was found that the conformation and molecular surface hydrophobicity of catalytic domains of TACE and MMPs were not obviously different, but the molecular surface electrostatic potential of catalytic domain of TACE and MMPs had obvious differences. The findings are helpful in the Rational Drug Design of TACE selective inhibitor.

Keywords

tumor necrosis factor-α converting enzyme / matrix metalloprotease / catalytic domain

References

[1] NewtonR. C., DeciccoC. P.. Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. J Med Chem, 1999, 42: 2295-314

[2] OnrustS. V., LambH. M.. Infliximab: A Review of its Use in Crohn’s Disease and Rheumatoid Arthritis. Bio Drugs, 1998, 10(5): 397-422

[3] MurrayK. M., DahlS. L.. Recombinant Human Tumor Necrosis Factor Receptor (P75) Fc Fusion Protein (TNFR:Fc) in Rheumatoid Arthritis. Ann Pharmacother, 1997, 31: 1335-8

[4] BlackR. A., RauchC. T., KozloskyC. J., et al.. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature, 1997, 385: 729-33

[5] MaskosK., Fernandez-CatalanC., HuberR., et al.. Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme. Proc Natl Acad Sci USA, 1998, 95(7): 3408-3412

[6] WoessnerJ. F.. Matrix Metalloproteinases and Their Inhibitors in Connective Tissue Remodeling. FASEB J, 1991, 5: 2145-54

[7] RothenbergM., NelsonA., HandeK.. New drugs on the horizon: matrix metalloproteinase inhibitors. Oncologist, 1998, 3: 271-4

[8] LovejoyB., WelchA. R., CarrS., et al.. Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol, 1999, 6(3): 217-221

[9] FengY., LikosJ., ZhuL., et al.. ¹H, ¹³C and ¹⁵N resonance assignments for a truncated and inhibited catalytic domain of matrix metalloproteinase-2. J Biomol NMR, 2000, 17(1): 85-86

[10] PavlovskyA. G., WilliamsM. G., YeQ. Z., et al.. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci, 1999, 8(7): 1455-1462

[11] RowsellS., HawtinP., MinshullC. A., et al.. Crystal structure of human MMP-9 in complex with a reverse hydroxamate inhibitor. J Mol Biol, 2002, 319(1): 173-181